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ABSTRACT

Using a recombinant vesicular stomatitis virus encoding eGFP fused in-frame with an essential viral
replication protein, the phosphoprotein P, we show that during passage in culture, the virus mutates
the nucleotide C289 within eGFP of the fusion protein PeGFP to A or T, resulting in R97S/C amino acid
substitution and loss of fluorescence. The resultant non-fluorescent virus exhibits increased fitness and
growth advantage over its fluorescent counterpart. The growth advantage of the non-fluorescent virus
appears to be due to increased transcription and replication activities of the PeGFP protein carrying the
R97S/C substitution. Further, our results show that the R97S/C mutation occurs prior to accumulation of
mutations that can result in loss of expression of the gene inserted at the G-L gene junction. These
results suggest that fitness gain is more important for the recombinant virus than elimination of
expression of the heterologous gene.
© 2012 Elsevier Inc. All rights reserved.

Introduction
Vesicular stomatitis virus (VSV) is a non-segmented negativestranded RNA virus in the family Rhabdoviridae and order
Mononegaviraies. It is widely used as a model pathogen for
understanding of myriad aspects of biology of negative-stranded
RNA viruses including viral genome transcription and replication,
innate and adaptive immune responses, host responses to viral
infections, viral evolution and many aspects of molecular biology
of eukaryotic cells. In recent years, VSV has also been used as a
viral vector for expression of heterologous genes, for vaccine
development and as an oncolytic agent for specific killing of
tumor cells (Barber, 2005; Geisbert et aI., 2010; Heiber et aI.,
2011; Lichty et aI., 2004).
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VSV possesses a simple genomic organization with five nonoverlapping genes (encoding the five structural proteins of the
virion) in the order of 3' -N-P-M-G-L-5'. The N protein binds the
viral genomic RNA to form a nucleocapsid template that is
recognized by the viral RNA-dependent RNA polymerase (RdRp)
composed of the P and L proteins, for transcription and replication
of the viral genome. The M and G proteins are required for
assembly and budding of infectious virus particles. Within the
viral genome, each gene is flanked by highly conserved upstream
transcription initiation signals and downstream transcription
termination signals that dictate synthesis of monocistronic,
capped, and polyadenylated viral mRNAs. Due to the modular
and non-overlapping gene organization, it has been relatively
straightforward to insert heterologous genes into the viral genome and recover infectious recombinant viruses. Consequently,
recombinant VSV expressing heterologous proteins (Geisbert
et aI., 2010; Lichty et aI., 2004; McKenna et aI., 2003) including
various proteins and antigens from other viral and bacterial
sources have been used to monitor immune responses and
protective immunity in vitro and in vivo.
Since the VSV RNA polymerase, like other viral RNA polymerases, lacks proof-reading activity and is error-prone, the
sequence integrity and expression of the foreign genes in VSV
are known to be compromised due to accumulation of mutations
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in these genes. Under normal conditions of selective pressure to
maintain the functionality of viral proteins, the VSV polymerase
introduces nucleotide substitutions in the viral genome resulting
in generation of viral quasispecies that may differ from each other
on the basis of growth potential and ﬁtness (Moya et al., 2000;
Steinhauer et al., 1989). The generation and characteristics of the
viral quasispecies and their ﬁtness in an infected host have been
considered to be important for understanding of viral evolution
and the dynamics of the viral population (Domingo et al., 2001;
Elena et al., 1996; Pfeiffer and Kirkegaard, 2006; Vignuzzi et al.,
2006). In addition, studies with VSV have also led to establishment and demonstration of important evolutionary principles
such as the Muller’s ratchet (Duarte et al., 1992; Muller, 1964),
the Red Queen Hypothesis (Clarke et al., 1994; van Valen, 1973),
the Competitive Exclusion Principle (Clarke et al., 1994; Gause
et al., 1971), among others (Domingo et al., 2001).
The manner in which VSV evolves and gains ﬁtness under
conditions of carrying foreign genes have not been investigated in
detail (Novella, 2003). How would the viral polymerase respond
to heterologous sequences fused with an essential viral protein to
maintain the reading frame of the essential viral protein to
generate viable viruses is unclear. Expression of heterologous
genes introduced at the G–L gene junction of VSV becomes
extinguished through mutation(s) at the transcription termination and/or initiation sites upstream of the introduced gene or
mutation(s) resulting in termination codon within the gene
(Quinones-Kochs et al., 2001). Recombinant VSV encoding eGFP
fused in-frame at the carboxy-terminus of the G protein, upon
passage, has been shown to eliminate the expression of eGFP due
to introduction of stop codon in the carboxy-terminus of the G
protein (Dalton and Rose, 2001). When eGFP is inserted in-frame
in the L protein, the resultant recombinant VSV becomes temperature-sensitive (Ruedas and Perrault, 2009). Although this
virus was shown to be genetically stable in four passages of
plaque-puriﬁed virus stocks, it grew to signiﬁcantly lower titers in
the fourth passage (Ruedas and Perrault, 2009), perhaps indicating accumulation of deleterious mutations in the genome of the
viruses in the population.
We had previously generated a recombinant VSV (VSV-PeGFP)
encoding P protein fused in-frame with eGFP sequences (Das
et al., 2006). Interestingly, passaging of the virus without plaquepuriﬁcation led to rapid loss of ﬂuorescence in infected cells and
generation of infectious VSV without ﬂuorescence, whereas plaque-puriﬁed VSV-PeGFP was relatively stable for at least twenty
passages in culture. Studies reported here were conducted to
understand the basis for the loss of ﬂuorescence and determine
whether the loss of ﬂuorescence imparts any growth advantage
and/or ﬁtness gain to the non-ﬂuorescent virus. Our results
identiﬁed a single nucleotide substitution (C289A/T) within the
eGFP sequence, generating a non-ﬂuorescent protein and conferring increased ﬁtness and growth advantage to the resulting virus.
To our knowledge, this is the ﬁrst description of a speciﬁc
nucleotide mutation in the inserted eGFP sequence that leads to
ﬁtness gain and growth advantage for the virus.

Results and discussion
A single nucleotide change (C289A/T) in eGFP coding sequence in
PeGFP fusion protein of VSV-PeGFP virus results in a
non-ﬂuorescent protein
We had previously described (Das et al., 2006) recovery of a
recombinant VSV (VSV-PeGFP) encoding PeGFP fusion protein in
which eGFP was fused in-frame following the amino acid 196 of
the viral P protein (Fig. 1A). In subsequent studies, when the virus
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Fig. 1. Identiﬁcation of a mutation within eGFP coding sequence in PeGFP fusion
protein of VSV-PeGFP virus. (A) Recombinant VSV genome constructs used in this
study. VSVwt, the wt VSV genome, with N, P, M, G and L shown in rectangular
boxes; VSV-PeGFP, genome encoding PeGFP in place of wt P; VSV-eGFP, eGFP was
inserted as an independent cistron at the G–L junction; VSV-PeGFP-M-MmRFP,
genome encoding PeGFP in place of wt P and MmRFP as an extra cistron at the G–L
junction. (B) Emergence and dominance of VSV-PeGFPng from the culture supernatant of plasmid recovered population of recombinant VSV-PeGFP. The supernatant containing recovered VSV-PeGFP virus (passage 0, P0) was passaged at 0.01
MOI on BHK-21 cells and the percentage of VSV-PeGFPng virus was determined by
plaque assay and counting of ﬂuorescent and non-ﬂuorescent viruses in various
passages. Histograms show the average data from three independent experiments.
(C) C289A is the only mutation found in full-length genome of VSV-PeGFPngR97S
compared to VSV-PeGFP virus. RNA genome of VSV-PeGFP and VSV-PeGFPngR97S
viruses was isolated directly from P0 supernatant (as in B). The viral RNAs were
subjected to RT-PCR, followed by nucleotide sequencing for the whole genome
using the primers shown in Table 2.

recovered from the transfected culture supernatants was passaged in cells without plaque puriﬁcation, we observed rapid loss
of green ﬂuorescence resulting in recombinant virus (VSVPeGFPng) that displayed non-ﬂuorescent [non-green (nG)] phenotype. The proportion of VSV-PeGFPng was only 0.1% at P1 but
increased to about 29% in P2. By passage 6, VSV-PeGFPng
represented approximately 99% of the total infectious particles
(Fig. 1B) as judged by enumerating the number of ﬂuorescent and
non-ﬂuorescent plaques in plaque assays.
To determine the molecular basis of the loss of eGFP ﬂuorescence in the infectious particles or in infected cells, twelve nonﬂuorescent and four ﬂuorescent plaques were isolated from a
plaque assay of P1 culture supernatant and the virus in these
plaques were ampliﬁed by passage in cells. During this passage,
the monolayer of cells infected with virus from non-ﬂuorescent
plaques did not display any ﬂuorescence while the cells infected
with virus from ﬂuorescent plaques were all ﬂuorescing green.
Both the ﬂuorescent (VSV-PeGFP) and non-ﬂuorescent (VSVPeGFPng) viruses synthesized full-length PeGFP protein in
infected cells and also packaged the PeGFP protein in the virions
as judged by radiolabeling and analysis of the viral proteins (data
not shown). The PeGFP coding region from the virus in the culture
supernatant of infected cells was then reverse-transcribed and
ampliﬁed by PCR and subjected to nucleotide sequencing.
Although no sequence changes were detected in the PeGFP fusion
protein of the viruses isolated from ﬂuorescent plaques, the
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Table 1
Mutations found in PeGFP, eGFP and MmRFP regions of VSV-PeGFP, VSV-eGFP and VSV-PeGFP-M-MmRFP viruses.
Virus

Phenotype

Mutation (amino acid change)

VSV-PeGFPn
VSV-PeGFPngn (emerged from the transfected culture supernatant
of recovered VSV-PeGFP)
VSV-PeGFPng (emerged from the plaque-puriﬁed
VSV-PeGFP during passaging)
VSV-PeGFP-M-MmRFP
VSV-PeGFP-M-MmRFPngr
VSV-PeGFP-M-MmRFPgnr

G
nG

Nonen
C289A (R97S)n or C289T (R97C) in eGFP

nG

C289T (R97C) and G608T (S203I) in eGFP

GR
nGR
GnR
GnR
GnR
GnR
nGnR
nGnR
nGnR
nGnR
G
nG
nG
nG
nG
nG
nG
nG

None
C289T (R97C) in eGFP
G659A (W220Stop) in M of MmRFP
TATG(A)7-TATA(A)7
G148T (E50Stop) in M of MmRFP
TATG(A)7-TAT(A)7
C289T (R97C) in eGFP and TATG(A)7-TAT(A)7 of MmRFP
C289T (R97C) in eGFP and C285A (Y95Stop) in M of MmRFP
C289T (R97C) in eGFP and TATG(A)7-TATGAAAAGAA of MmRFP
C289T (R97C) in eGFP and TATG(A)7-TATGACAAAAA of MmRFP
None
A545C (H182P) in eGFP
TATG(A)7-TATG(TAAAATA)
TATG(A)7-TATG(TAAAAATA) and T656G (M219R) in eGFP
TATG(A)7-TATG(TACAATA) and C321A (Y107Stop) in eGFP
TATG(A)7-TATG(TACAATA)
TATG(A)7-TATG(TAAAATA) and A136T (K46Stop) in eGFP
TATG(A)7-TATG(TAAAATA) and G184A (V62M) in eGFP

VSV-PeGFP-M-MmRFPngnr

VSV-eGFP
VSV-eGFPng

The (n) indicates the viruses used for full-length genome sequence determination and for competition assays.

PeGFP coding region in the plaque-puriﬁed VSV-PeGFPng viruses
contained only a single nucleotide substitution (C289A) resulting
in arginine to serine (R97S) change at position 97 in the eGFP
sequence of the fusion protein (Table 1). Interestingly, only the
same mutation was also found in VSV-PeGFPng virus from later
passages (P5 and P6) indicating that the mutation is stable and
rendered the PeGFP fusion protein non-ﬂuorescent.
Results from studies using a virus with a different genomic
background also supported the above contention. The recombinant VSV (VSV-PeGFP-M-MmRFP, Fig. 1A) encodes PeGFP in place
of P and MmRFP (a fusion protein containing monomeric RFP
fused in-frame at the carboxy-terminus of the viral M protein) at
the G–L gene junction (Das et al., 2009). Majority of the recombinant VSV-PeGFP-M-MmRFP from plasmid-transfected supernatant exhibited both ﬂuorescences (green due to PeGFP and red
due to MmRFP) in infected cells but upon passage in culture, virus
plaques exhibiting dual-ﬂuorescence (GR), only red-ﬂuorescence
(nGR), only green-ﬂuorescence (GnR) and no ﬂuorescence (nGnR)
appeared. Interestingly, examination of virus in at least twelve
plaques that were only red-ﬂuorescent (nGR, due to loss of green
ﬂuorescence) revealed that they contained C289T mutation in the
eGFP sequence leading to R97C substitution in the protein
(Table 1). Surprisingly, none of the twelve plaque-puriﬁed nGR
viruses from this genomic background contained the C289A
nucleotide substitution as was observed for VSV-PeGFPng virus.
Since we observed C289T mutation in all the plaque-puriﬁed
VSV-PeGFP-M-MmRFPngr viruses and C289A mutation in all the
plaque-puriﬁed VSV-PeGFPng viruses, we investigated whether
this C289A/T mutation is speciﬁc and dependent on the viral
genomic background. In three further independent virus recovery
and passaging studies using both viruses, we observed similar
pattern of loss of ﬂuorescence with passage as shown in Fig. 1B.
Sequence analyses of eight each of plaque-puriﬁed VSV-PeGFPng
and VSV-PeGFP-M-MmRFPngr (only red-ﬂuorescent) viruses from
P1 and P4 culture supernatants revealed the presence of either
C289A or C289T mutation in eGFP coding region of PeGFP,
suggesting that C289 could be mutated to either A or T independent of the genomic background of the virus. Again, no other
nucleotide substitution was detected in PeGFP coding region of
these mutant viruses.

Using VSV-eGFP virus (Das et al., 2006), which contains eGFP
gene at the G–L gene junction as an extra gene, similar passaging
of transfected culture supernatant led to the development of nonﬂuorescent plaques, although only 0.01%–1% of the plaques were
non-ﬂuorescent in the supernatants of P2–P12. The overall
growth of non-ﬂuorescent VSV (VSV-eGFPng) was similar to that
of the ﬂuorescent VSV (VSV-eGFP) (data not shown). RT-PCR
ampliﬁcation of viral genomes isolated from at least twelve
different plaques selected randomly from two different passages
(P3 and P8) revealed the presence of a variety of mutations
leading to the loss of green ﬂuorescence (Table 1). However, none
of these VSV-eGFPng viruses contained C289 mutation; instead
they contained mutations resulting in amino acid substitution,
introduction of stop codon within eGFP sequence, and/or
mutation(s) in the transcription termination signal. Similar types
of mutations have been detected in recombinant VSVs encoding
heterologous proteins at the G–L gene junctions (Quinones-Kochs
et al., 2001). It appears that C289A/T mutation resulting in R97S/C
substitution in eGFP is only observed in the context of PeGFP
fusion protein, which is required for VSV replication.
Thus, from multiple independent virus recovery and passaging
experiments using at least two different virus genomic backgrounds, we have observed that the nucleotide C289 in eGFP
coding sequence of the PeGFP is mutated to either A (transversion
mutation) or T (transition mutation) resulting in amino acid
substitution of R97S/C. Since transversion mutations are less
frequent as compared to transition mutations (Domingo et al.,
1978; Kuge et al., 1989; Schneider and Roossinck, 2000), the
results suggest that the selective pressure to mutate this particular nucleotide such that the resulting protein is non-ﬂuorescent
is strong.
R97S/C mutation in eGFP confers growth advantage to
VSV-PeGFPng virus
The rapid generation of VSV-PeGFPng virus with R97S/C
substitution in eGFP sequence led us to investigate if the mutation
conferred any growth advantage to the viruses. To examine this,
we performed single step growth kinetics studies of the viruses
(wt VSV, VSV-PeGFP, VSV-PeGFPngR97S, and VSV-PeGFPngR97C)
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using high MOI infection. Although the kinetics of growth of the
four viruses is found to be similar, VSV-PeGFP grew to titers that
were about 8-fold less than the wt VSV, conﬁrming previous
observation (Das et al., 2006). On the other hand, VSV-PeGFPng
viruses harboring either R97S or R97C mutation grew to comparable titers that were close to those of the wt VSV (Fig. 2A). The
difference in growth potential of VSV-PeGFP and VSV-PeGFPng
viruses was signiﬁcant (po0.01), indicating that R97S/C substitution in eGFP sequence of PeGFP fusion protein not only rendered
the protein non-ﬂuorescent but also conferred growth advantage
to the virus. Similar growth advantage was also observed for VSVPeGFPng virus in multistep growth kinetics analysis at low MOI
(Fig. 2B). Full-length genome sequence analysis revealed that the
VSV-PeGFPng differed from VSV-PeGFP by the presence of only the
C289A mutation (Fig. 1C). Thus, it appears that R97S/C mutation in
eGFP sequence of the fusion protein confers growth advantage to
the resulting viruses.
The R97 residue in eGFP (equivalent to R96 residue in GFP
sequence) is known to facilitate rapid formation and stability of
the eGFP chromophore consisting of residues S65-Y66-G67
(Barondeau et al., 2003; Ormo et al., 1996) and it has been shown
that R96A substitution in GFP protein results in a dominant
negative protein with no ﬂuorescence (Barondeau et al., 2003).
Clearly, the data presented here suggests that the loss of ﬂuorescence in PeGFP or some structural alterations in the fusion protein
due to R97S/C substitution results in a fusion protein that helps
the virus grow better. Although loss of green ﬂuorescence in viral
fusion proteins have not been systematically examined during
viral passages in cell culture, R97C along with several other
mutations including gene truncation and deletion were detected
in porcine respiratory and reproductive syndrome virus encoding
eGFP fused in-frame with the viral non-structural protein 2 (Fang
et al., 2008, 2006; Kim et al., 2007). It is thus possible that a
properly folded chromophore of eGFP may somehow negatively
affect the function of the PeGFP protein and the VSV-PeGFP virus
introduces amino acid substitutions to alter or destabilize the
chromophore to enhance its growth.
Increased ﬁtness of VSV-PeGFPng over VSV-PeGFP
in competition assay
Since VSV-PeGFPng virus grew to higher titers, we examined if
this virus evolved by acquiring increased ﬁtness over that of its
ﬂuorescent counterpart. Fitness studies with recombinant VSVs
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harboring rearranged order of P, M and G genes have revealed
that growth curve comparisons are not necessarily useful in
measuring the ﬁtness of a virus, while viral ﬁtness can be
determined in direct head-to-head competition assays (Novella
et al., 2004a). Thus, in order to determine if VSV-PeGFPng
acquired increased ﬁtness over VSV-PeGFP, we performed headto-head competition assay between the two viruses. Stocks of
plaque-puriﬁed VSV-PeGFP and VSV-PGFPngR97S viruses whose
full-length genome sequence had been determined (Table 1) were
prepared and used in these experiments. As shown in Fig. 3A,
when the two viruses (VSV-PeGFP and VSV-PeGFPng) were mixed
at 1:1 ratio of infectious particles and allowed to co-infect cells at
the low MOI of 0.01, the ratio of non-green:green (ng:g) infectious
viruses in the resulting supernatant changed from 1:1 in P0 (the
starting inoculum) to 10:1 in passage 1 (P1). Upon further passage
of P1 supernatant at the same low MOI of 0.01, the ratio of ng:g
virus changed to 80:1, 680:1, 2300:1 and 22,000:1 in the supernatants of P2–P5 passages, respectively. These results indicate
that the VSV-PeGFPng virus out-competed the VSV-PeGFP virus in
co-infection experiments very efﬁciently and became the predominant virus in the culture quickly. By calculating the relative
ﬁtness of the two viruses and the ﬁtness difference (Wd) value
between them as described in the materials and methods, we
found that the VSV-PeGFPng virus with a ﬁtness difference value
of 2.62 at P1 is more ﬁt than the VSV-PeGFP virus.
Since ﬁtness of a virus is also dependent on MOI (Novella et al.,
2004a), we conducted a similar experiment using a high MOI of 5.
Although the ratio of ng:g virus shifted from 1:1 in P0 to 16:1 in
P5 supernatant (Fig. 3B), the calculated ﬁtness difference value of
1.45 at P1 indicated that the VSV-PeGFPng is still more ﬁt than
the VSV-PeGFP virus at high MOI. It should be noted that with
high MOI, the ﬁtness difference is somewhat less and the ratios of
ng:g virus is not as dramatic as those seen with low MOI passage.
This is most likely due to co-infection of same cells with the two
viruses and possible complementation of the less ﬁt virus by the
higher ﬁtness virus as has been observed previously (Novella
et al., 2004a). These results further show that complementation at
high MOI may have somewhat overshadowed the difference in
ﬁtness between the two competing viruses as has been described
earlier (Novella et al., 2004b).
It is possible that the reduced level of VSV-PeGFP and/or
increased level of VSV-PeGFPng in the competition assays may
also have been a result of mutation(s) in the eGFP region as seen
in Fig. 1B rather than the acquisition of increased ﬁtness of the

Fig. 2. R97S/C mutation in eGFP confers growth advantage to VSV-PeGFPng virus. (A) One-step growth curve of wt VSV, VSV-PeGFP, VSV-PeGFPng containing C289A (VSVPeGFPngR97S) or C289T (VSV-PeGFPngR97C) mutation. Infection was performed in BHK-21 cells at MOI of 5, supernatants were collected at indicated time points and viral
yields were determined by plaque assay in fresh BHK-21 cells. Error bars represent the standard error of mean from 3 independent experiments. (B) Multi-step growth
curve. Viruses shown in A were allowed to infect BHK-21 cells separately at MOI of 0.01. Viral titers were determined and shown as described in A.
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Fig. 3. Increased ﬁtness of VSV-PeGFPng over VSV-PeGFP in competition assay.
(A) Competition assay at low MOI. BHK-21 cells were co-infected at an MOI of 0.01
with a 1:1 mixture of plaque-puriﬁed VSV-PeGFP and VSV-PeGFPng (P0). At
16 hpi, supernatant (P1) was collected and titers VSV-PeGFP and VSV-PeGFPng
viruses were determined in fresh BHK-21. Supernatant of P1 and subsequent
passages were used to infect new BHK-21 cells at the same MOI of 0.01 to produce
P2 to P5. Histograms show the average relative levels of VSV-PeGFP and
VSV-PeGFPng viruses from three independent experiments. The numbers indicate
the average ratio of the two viruses as determined by plaques assay in BHK-21
cells for each passage. (B) Competition assay at high MOI. The assay was done at
MOI of 5 and the data were obtained as in A. (C) Kinetics of loss of green
ﬂuorescence in clonally puriﬁed VSV-PeGFP. Isolated pure green VSV-PeGFP was
used to infect and passage in BHK-21 cells at MOI of 0.01. Percentage of green over
non-green virus was determined as described in Fig. 1B.

VSV-PeGFPng virus. To examine if this is occurring, we used
plaque-puriﬁed VSV-PeGFP and passaged at low MOI (0.01) in
cells. Infectious ﬂuorescent and non-ﬂuorescent viruses were
then enumerated by plaque assay and examination under ﬂuorescent microscope. Examination of 500–1000 plaques at each
passage did not detect any nG phenotype plaque during the ﬁrst
18 passages (data not shown), indicating that the plaque-puriﬁed
VSV-PeGFP is stable for at least 18 passages in culture. These
results suggest that in the competition assays shown in Fig. 3A
and B, the exponential increase in the number of VSV-PeGFPng
virus was not due to genesis of VSV-PeGFPng from VSV-PeGFP but
rather was the consequence of the better ﬁtness and higher

growth potential of the VSV-PeGFPng virus as compared to VSVPeGFP virus. Interestingly, upon further passage of plaque-puriﬁed VSV-PeGFP, non-ﬂuorescent progeny began to appear in P20,
representing about 0.3% of the total infectious progeny. The
proportion of the non-ﬂuorescent virus increased with passage
thereafter, becoming 99% or greater by P28 (Fig. 3C). Sequence
analysis of PeGFP region of the viral genome from at least ten
non-ﬂuorescent plaques picked randomly from P20 to P28 supernatants revealed the same mutation (C289T) as observed earlier
(Fig. 1C), resulting in substitution of R97C within the eGFP region
of PeGFP and rendering the protein non-ﬂuorescent. An additional
mutation (G608T resulting in S203I substitution in eGFP) was also
detected in these clones (Table 1). Nevertheless, the results
demonstrate that once C289 in eGFP is mutated, the resultant
virus gains large selective advantage and quickly increases its
frequency in the population.
The rapid rate of loss of green ﬂuorescence upon passage of the
population of VSV-PeGFP in the culture supernatants of transfected cells as compared to the slow rate of loss of ﬂuorescence of
plaque-puriﬁed VSV-PeGFP could be the consequence of different
evolutionary factors. It is possible that insertion of eGFP in the VSV
P protein results in virus growth constraints and ﬁtness loss. The
virus then escapes from these constraints by mutating its genome
as soon as it is generated from the plasmid DNA. The synergistic
effects of viral growth constraint and ﬁtness loss may drive the
viral polymerase to incorporate the C289A/T mutation generating
a small population of VSV-PeGFPng viruses in the culture. Due to
growth advantage and ﬁtness acquisition of the resulting nG virus,
it replicates to higher levels and rapidly out-competes its ﬂuorescent counterpart upon passage. It then predominates in the
population at a faster rate due to the advantageous mutation
(C289A/T) than the de novo generated variants (Dutta et al., 2008).
When the population of VSV-PeGFPng increases in subsequent
passages, VSV-PeGFPng has more chance to gain ﬁtness over
VSV-PeGFP as a result of larger population transmission (Novella
et al., 1995). The VSV-PeGFPng then overwhelms the population
and consequently, VSV-PeGFP disappears. The same trend probably occurs in the population of purely clonal VSV-PeGFP with a
much slower speed, likely due to the fact that the cloned virus
may have adapted to the cells to some extent through several
rounds of replication. Alternatively, it is possible that the recombinant virus population after being regenerated from DNA plasmid
may undergo more selective pressure compared to the clonally
puriﬁed ones. The newly generated viruses from plasmid DNA
must adapt to the new environment in cell culture as it was
documented for VSV (Dutta et al., 2008; Gao et al., 2006).
Heterologous sequences such as those of eGFP may compromise
the functions or properties of the viral P protein as reported for
VSV G protein containing foreign epitope insertion from HIV-1
(Schlehuber and Rose, 2004) and therefore the virus may incorporate mutation(s) to generate the protein with higher activity.
Mutation at C289 of eGFP occurs prior to mutation in M-mRFP
in the context of a virus genome encoding two ﬂuorescent fusion
proteins
VSV-PeGFP-M-MmRFP virus synthesizes both PeGFP and
MmRFP fusion proteins (in addition to the wild type M protein)
in infected cells. Unlike PeGFP whose function is required for viral
genome transcription and replication, the MmRFP fusion protein
is not required during the life cycle of the virus (Das et al., 2009).
Thus, the use of this dual-ﬂuorescent virus allowed us to investigate if C289 position in eGFP is susceptible to mutation by the
viral polymerase and if this mutation occurs earlier than
mutation(s) appearing in the MmRFP coding region of the viral
genome. Cells infected with VSV-PeGFP-M-MmRFP virus stock
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Fig. 4. Mutation at C289 of eGFP occurs ﬁrst in the context of VSV-PeGFP-M-MmRFP encoding two ﬂuorescent fusion proteins. (A) Kinetics of the emergence of viruses
with all possible ﬂuorescence phenotypes from plasmid-recovered recombinant green–red (GR) VSV-PeGFP-M-MmRFP. Culture supernatant of plasmid-recovered VSVPeGFP-M-MmRFPgr (considered as P0) was used to infect and serially passage at an MOI of 0.01 up to passage 12. The percentage of each phenotype virus was determined
by plaque counting on BHK-21 under ﬂuorescent microscope. Histograms show the average data from two independent experiments. (B) Analysis of viral RNA in cells
infected with recombinant viruses. BHK-21 was infected with 5 MOI of wt VSV (lane 1), GR (VSV-PeGFP-M-MmRFP) (lane 2), nGR (VSV-PeGFP-M-MmRFPngr) (lane 3), GnR
with Stop codon in MmRFP region (VSV-PeGFP-M-MmRFPStopgnr)(lane 4), GnR with bicistronic G-MmRFP (VSV-PeGFP-M-MmRFPBicisgnr) (lane 5) and nGnR carrying
C289T together with bicistronic G-MmRFP (VSV-PeGFP-M-MmRFPBicisngnr) or with stop codon in MmRFP region (VSV-PeGFP-M-MmRFPStopngnr) (lane 6 and 7). RNAs
were labeled with 3H-uridin at 5 hpi for 6 h. M and P mRNAs migrate together, PeGFP and MmRFP also have the same mobility; G mRNA in VSV-PeGFP-M-MmRFP is
shortened in length compared to wt VSV, due to the insertion of MmRFP at G–L junction. (C) Analysis of viral proteins in cell infected with recombinant viruses. Infection
conditions and viruses used in lane 2–8 are the same as in panel A, lane 1–7. Lane 1 contains proteins from uninfected cells. Proteins were labeled with 35S-Met/Cys at 5 hpi
for 4 h. Similar amounts of infected cells extracts were analyzed. Viral proteins and size markers (in kDa) are shown. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)

recovered from transfected culture supernatant (without plaque
puriﬁcation) expressed both green and red ﬂuorescence and
greater than 99.5% of the plaques of P1 exhibited both ﬂuorescences. However, upon passage, the green–red (GR) phenotype of
the virus plaques changed and all other possible phenotypic
combinations [nongreen–red (nGR), green–nonred (GnR) and
nongreen–nonred (nGnR)] of the virus emerged. The relative
levels of these viruses in subsequent passages changed from
approximately 97.8:0.8:1.4:0 for the GR:nGR:GnR:nGnR viruses,
respectively, in P2 to 28:70:1.8:0.2 in P4, indicating that the nGR
phenotype dramatically increased in P4 (Fig. 4A). During these
early passages (P8 or earlier), no substantial increase in GnR or
nGnR virus was detected (Fig. 4A), indicating that nGR virus
appears ﬁrst and dominates in the population. Based on the
kinetics of appearance of GR:nGR:nGnR from P2 (97.8:0.8:0) to
P4 (28:70:0.2) and P12 (3:10:78) (Fig. 4A), it can be seen that the
nGnR virus appears after nGR virus.
Sequence analysis revealed that the PeGFP region of the nGR
virus from any of the passages possessed only the C289T mutation (Table 1), which was identiﬁed as described above. MmRFP
coding region was unaltered in these viruses that displayed red
ﬂuorescence phenotype. Several mutations resulting in introduction of stop codon in M protein of MmRFP as well as mutations in
the transcription termination signals upstream of the MmRFP
gene that led to loss of red ﬂuorescence were detected in GnR
viruses (Table 1). Viruses with nGnR phenotype possessed a

variety of mutations in addition to the mutation at C289 of eGFP
(Table 1). Overall, the results suggest that C289 of eGFP was
primarily mutated in the dual-ﬂuorescent virus prior to appearance of mutations in the MmRFP region of the viral genome.
Since viruses with various phenotypes contained mutations in
the transcription termination signals and/or mutations leading to
stop codon in MmRFP, we examined the RNA and protein proﬁles
in cells infected with these infectious viruses to determine the
molecular basis of loss of ﬂuorescence of these viruses. In this
analysis, we examined viruses that contained mutations in the
transcription termination signals and/or mutations resulting in
stop codon in M region of MmRFP fusion protein. Examination of
mRNA proﬁles showed that viruses with mutations in the transcription termination signals synthesized a bicistronic mRNA,
G-MmRFP (Fig. 4B, lanes 5 and 6) with concomitant loss or
undetectable levels of G and MmRFP mRNAs. Examination of
virally encoded proteins in infected cells revealed that viruses
with stop codon in MmRFP and/or with mutations in the transcription termination signals did not synthesize detectable levels
of MmRFP fusion protein (Fig. 4C, lanes 5–8) compared to the wt
VSV-PeGFP-M-MmRFP and VSV-PeGFP-M-MmRFPngr (Fig. 4C,
lanes 3–4). The levels of G protein in cells infected with viruses
that synthesized the bicistronic mRNA was lower (Fig. 4C, lanes
6 and 7). Importantly, in all these virus-infected cells, full-length
PeGFP fusion protein was synthesized (Fig. 4C, lanes 3–8) independent of its ﬂuorescence phenotype.
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Insertion of stop codons or alterations of the transcription
regulatory sequences upstream of the inserted gene has been
shown to be the predominant mechanisms employed by VSV to
eliminate the expression of heterologous genes inserted at the
viral gene junctions (Quinones-Kochs et al., 2001; Wertz et al.,
2002). The results presented here using recombinant VSVs having
different genomic backgrounds further reconﬁrm these observations. However, with the use of VSV encoding two different
ﬂuorescent proteins, it appears that the viral polymerase ﬁrst
incorporates mutation(s) to generate virus with greater ﬁtness
advantage and then incorporates mutation to eliminate expression of genes inserted at the gene junction.

PeGFPng exhibits increased activity in P functions
compared to PeGFP
Results from growth kinetics and competition experiments
suggested that VSV-PeGFPng exhibited growth advantage and
ﬁtness gain over VSV-PeGFP virus. Therefore, we hypothesized
that PeGFP fusion protein containing the R97S/C mutation may
possess increased activity as a subunit of the viral polymerase. To
test this hypothesis, we examined the activity of PeGFPng fusion
protein and compared to that of PeGFP in VSV genome replication
and transcription. The PeGFPng mutant coding sequence was
cloned under T7 RNA polymerase promoter in pGEM3 vector and
the ability of PeGFPngR97S protein in supporting replication of VSV
DI particle RNA or transcription of a VSV minireplicon was
compared to that of PeGFP. Cells were infected with vTF7-3 and
subsequently transfected plasmids encoding N, L, and PeGFP,
PeGFPng or empty vector. For replication assay, the cells were
then infected with DI particles and radiolabeled. The radiolabeled
RNAs were immunoprecipitated with anti-N antibody and
analyzed as described previously (Pattnaik and Wertz, 1990). For
transcription analysis, the cells were co-transfected with a minireplicon-encoding plasmid and the transcription products were
radiolabeled and analyzed as before (Hwang et al., 1998). Results
show that the PeGFPngR97S protein exhibits approximately threefold higher activity in replication (Fig. 5A) as compared to the wt
PeGFP protein. A similar increased activity in transcription was also
observed for the mutant protein as compared to the wt protein
(Fig. 5B). Under these experimental conditions, both proteins were
expressed at similar levels in transfected cells (Fig. 5A and B). Since
full-genome sequencing of the VSV-PeGFP and VSV-PeGFPng
viruses revealed no sequence alterations other than the C289A
(R97S) change, the results suggest that the higher growth and
competitiveness of VSV-PeGFPng virus is primarily due to the
relatively increased activity of PeGFPng fusion protein in viral
genome transcription and replication as compared to PeGFP.

Fig. 5. Replication and transcription activity of PeGFPngR97S mutant protein.
(A) DI particle RNA replication. BHK-21 cells were infected with vTF7-3 and
co-transfected with plasmids encoding VSV N, L, and PeGFP (WT), PeGFPngR97S
(nG) or pGEM3 empty vector (EV). At 10–12 hpt, cells were infected with DI
particles, followed by labeling with 3H-uridine for 12 h. Labeled RNAs were
immunoprecipitated by anti-N antibody (1:100), separated on urea–agarose gel
and detected by ﬂuorography (A, top panel). The products were detected as a
doublet representing the þve and  ve sense DI RNA replication products.
Histogram (bottom panel) shows the quantitative levels of DI replication products.
Error bars represent the standard error of mean from 3 independent experiments.
(B) Transcription of VSV minigenome. 10 mg of p10BN encoding a VSV minireplicon was co-transfected with pN, pL, and pPeGFP (WT), pPeGFPngR97S (nG) or
pGEM3 empty vector (EV). At 8–10 hpt, cells were labeled with 3H-uridine for 12 h
in the presence of actinomycin D. Labeled transcription products were extracted
and analyzed by electrophoresis and detected as in A (top panel). Histogram
(bottom panel) shows the quantitative levels of transcription products. Error bars
represent the standard error of mean from 3 independent experiments. Expression
level of PeGFP (WT) or PeGFPngR97S (nG) in the transfected cells was examined
by Western blotting. Levels of b-actin served as loading control.

due primarily to enhanced activity of the PeGFPng in viral
genome transcription and replication.
Our results demonstrate that a gene of interest in the form of a
fusion gene can be stably expressed from clonally puriﬁed VSV
stock for at least twenty passages. VSV encoding different ﬂuorescent proteins could be further used in evolutionary studies for
better understanding of viral adaptability, gain/loss of ﬁtness,
growth capacity and stability of inserted genes in recombinant
VSVs carrying foreign genes.

Conclusions
The following conclusions can be derived from the results
presented here. (1) The VSV polymerase speciﬁcally mutates C289
of eGFP in the context of PeGFP fusion gene to either an A or T
residue. This leads to amino acid substitution R97S/C in eGFP and
loss of ﬂuorescence. (2) The non-ﬂuorescent virus with R97S/C
substitution gains growth advantage and ﬁtness as compared to
its ﬂuorescent counterpart. (3) In recombinant VSV encoding two
heterologous proteins, one as a fusion protein required for
replication and another as a fusion protein not required for
replication, the virus preferentially mutates ﬁrst the fusion
protein required for replication which allows the virus to gain
growth advantage and ﬁtness before mutating the other fusion
protein. (4) The growth advantage of the non-ﬂuorescent virus is

Materials and methods
Cell culture, viruses, antibodies, and reagents
Baby hamster kidney (BHK-21) monolayer cells were maintained in MEM supplemented with 5% FBS and 1  PKS antibiotics
(penicillin, 100 units/ml; kanamycin, 20 units/ml; and streptomycin, 20 units/ml). Stocks of recombinant vaccinia virus vTF7-3
(Fuerst et al., 1986) was prepared as described before (Hwang
et al., 1998). Indiana strain of wild type VSV and defective
interfering particles (DI-T) of wt VSV were prepared as previously
described (Pattnaik and Wertz, 1990). Plasmids encoding VSV and
its derivatives with ﬂuorescent proteins have been described
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earlier (Das et al., 2006; Das et al., 2009; Lawson et al., 1995).
Rabbit anti-VSV P polyclonal antibody has been described before
(Das and Pattnaik, 2005). Anti-VSV N (10G4) monoclonal antibodies were kindly provided by Dr. D. Lyles.
Plasmid constructs and virus recovery
pGEM3 was used for cloning of PeGFP sequences derived from
various recombinant viruses. Viral genomic RNAs from culture
supernatants were used for reverse transcription-polymerase
chain reaction (RT-PCR) ampliﬁcation of PeGFP region using
P(þ) and P( ) primers (Table 2). The ampliﬁed DNAs are then
cloned into pGEM3 vector using EcoRV restriction site. The
authentic sequence of the PeGFP clones was conﬁrmed by
nucleotide sequencing. Plasmids pN, pL, and p10BN encoding
the N, L proteins or the transcription-competent minireplicon
have been described previously (Hwang et al., 1998; Pattnaik
et al., 1992). Cells were transfected with plasmid DNAs using
Lipofectamine2000 (Invitrogen) as per manufacturer’s protocol.
Virus recovery and identiﬁcation of recovered viruses were
conducted as previously described (Das and Pattnaik, 2004).
Isolation and ampliﬁcation of clonally pure virus stocks and growth
kinetics analysis
Single plaques from VSV-PeGFP, VSV-eGFP, VSV-PeGFP-MMmRFP viruses and their mutant derivatives were selected under
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ﬂuorescence microscope and isolated using a sterile Pasteur
pipette. Virus particles in the agarose plug were placed in virus
growth medium (DMEM containing 2% fetal bovine serum and 1X
PKS) and were frozen at  80 1C. To prepare clonally pure virus
stocks, the thawed growth medium containing virus plaque was
used as inoculum to infect a monolayer of BHK-21 cells and virus
titers in the supernatants were determined by plaque assay.
Growth kinetics of all viruses used in this study were determined
by infection at MOI of 5 (for single-step growth) and 0.01 (for
multi-step growth) following the protocol described before (Das
and Pattnaik, 2004).

Virus passaging, ﬁtness determination and calculation
of ﬁtness gain
Fitness of VSV-PeGFP and VSV-PeGFPng was determined via
competition assay. Viruses were mixed together at the ratio of 1:1
and this mixture (passage 0, P0) was allowed to co-infect BHK-21
cell monolayer at an MOI of 0.01. Infection of cells with individual
viruses at the same MOI was also carried out in parallel for monoinfections. At 16 h post infection (hpi), supernatant was collected
and designated as P1 and virus titers were determined. The P1
virus was then used to infect new BHK-21 cell monolayer at same
MOI of 0.01 to produce P2. The process was repeated to produce
P5 viruses. Similarly, the competition assay was also performed at
an MOI of 5 in which the supernatant of each passage was
harvested at 8 hpi. The titer of each virus in competition or

Table 2
Primers used in this study.
Primer name

Primer nucleotide sequences

Used for

MfeI-N-For
M2481Rev
eGFP188-Rev
P2600For
G-4518-For
L-5093-Rev
Le( þ) For
N440For
N533Rev
MfeI-N-For
eGFP188-Rev
P2600For
P1430R
P(  )
M2481Rev
VSV2160For
VSV2523For
G4124For
G-NdeI Rev
G4548F
G4668Rev
G-4518-For
L-StuI For
L-DrdI Rev
L-5093-Rev
L-AclI Rev
L-BclI For
L-EcoRI For
L-825I-NotIR
L-PciI Rev
L630II-NotIR
L-AseI For
L-BstXI For
L-ScaIF
L-SalI Rev
Tr( þ) Rev
P( þ )-For
P(  )

AGAAGACAATTGGCAAGTATGC
GTGTAGACTCATACAAGAC
GTCACGAGGGTGGGCCAGGG
ATTATGAAGGAGCGCCAG
GTTCTCCGAGTTGGTA
CTGCCTCTTTGTCCACTTC
ACGAAGACAAACAAACCATTATTA
CACAAATGCCTGAATACAG
GCTGGAAGACCGTGTTCTCC
AGAAGACAATTGGCAAGTATGC
GTCACGAGGGTGGGCCAGGG
ATTATGAAGGAGCGCCAG
AACTCTATGAGTGCTTGAAAACAC
ATATATCTGCAGATATCTGTTACTTTTTTTCATAGTCTACAGAGAATATTTG
GTGTAGACTCATACAAGAC
GTACAATCAGGCGAGAGTCA
GATCACATGTACATCGGAATG
GGAACTTGGCTGAATC
CAGTGGGGCATATGTAATTG
GATCTCTTTGCTGCAG
GGTATCACAAGTTGATTTGG
GTTCTCCGAGTTGGTA
AGAATCAAGGCCTTTAGTCC
AGGATGACCCCAATGTCTG
CTGCCTCTTTGTCCACTTC
GTAATTCTACAACGTTTCTCG
CACACTGATCAATTCAACCTC
TAAGTGAATTCAAATCAGGCAC
AAAATGAGCTACGGTGAGAG
GAGTAGCTGAACATGTCCAC
TGATCTAGTAAGAGAAAGGAATG
AGACGGATTAATGAGAGCAAG
CAAGGACTTGGGACTATTTC
AGAAGTGGAGTACTAGAGG
TTTGAACTAAGTCGACCGTC
ACGAAGACCACAAAACCAG
ATATATGGTACCGATATCATGGATAATCTCACAAAAGTTCGTGAG
ATATATCTGCAGATATCTGTTACTTTTTTTCATAGTCTACAGAGAATATTTG

Ampliﬁcation and sequencing of the PeGFP region

Primer sequences are in 50 –30 direction. Restriction enzyme sites in the primers are underlined.

Ampliﬁcation and sequencing of the MmRFP or
eGFP region at G–L junction
Ampliﬁcation and sequencing of the fragment
spanning nucleotides 1–2500 of full-length VSV
genome

Ampliﬁcation and sequencing of the fragment
spanning nucleotides 2180–4670 of full-length
VSV genome

Ampliﬁcation and sequencing of the fragment
spanning nucleotides 4530–6920 of full-length
VSV genome

Ampliﬁcation and sequencing of the fragment
spanning nucleotides 6730–9080 of full-length
VSV genome

Ampliﬁcation and sequencing of the fragment
spanning nucleotides 8950–11161 of full-length
VSV genome

Cloning of PeGFP fragment
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mono-infection at each passage was determined by plaque assay
on BHK-21 and green and nongreen plaques were counted on
ﬂuorescence microscope. Approximately 500–1000 plaques were
examined for early passage virus (P0–P1) and 105–106 plaques for
later passage virus (P2–P5). The data shown in this study were the
average of three replicates of plaque assay. Relative ﬁtness values
(W) were calculated based on the amount of a speciﬁc VSV
phenotype in a competition infection divided by the amount of
the same virus resulting from a mono-infection under the same
experimental conditions (Kong et al., 2008). The formulae are:
ðGc=GmÞ
2
ðGc=GmÞ þ ðnGc=nGmÞ
ðnGc=nGmÞ
2
W nG ¼
ðnGc=nGmÞ þðGc=GmÞ
WG ¼

where, WnG and WG represent nongreen and green virus relative
ﬁtness values; Gc and nGc represent the amount of VSV-PeGFP
and VSV-PeGFPng particles, respectively, in competition infection; Gm and nGm represent the amount of VSV-PeGFP and
VSV-PeGFPng particles, respectively, in mono-infection. The ratio
of relative ﬁtness value of each virus in the competition assay is
measured via the ﬁtness difference, Wd¼WNG/WG. A value of
Wd 41 indicates that VSV-PeGFPng is more ﬁt than VSV-PeGFP
and a value of Wd o1 indicates that VSV-PeGFPng is less ﬁt than
VSV-PeGFP.
To determine the kinetics of non-ﬂuorescent virus emergence,
initially recovered culture supernatants (passage 0 (P0)) of VSVeGFP, VSV-PeGFP-M-MmRFP, and VSV-PeGFP as well as purely
clonal VSV-PeGFP from an isolated plaque (P0) were allowed to
infect BHK-21 cell monolayer at an MOI of 0.01. At 16–20 hpi,
supernatant was collected and designated P1. The P1 then was
used to infect new BHK-21 cell monolayer at same MOI of 0.01 to
produce P2 and subsequent passages were performed similarly.

and the labeled proteins were analyzed by 10% SDS-PAGE and
detected by ﬂuorography (Das et al., 2010).
Reverse transcriptase-polymerase chain reaction (RT-PCR) and
sequencing
Viral RNAs from the viruses in the culture supernatant were
extracted by TRIzol LS (Invitrogen) as per manufacturer’s protocol. RT reactions were performed using Superscript III RT (Invitrogen), followed by PCR with Faststart high ﬁdelity PCR system
(Roche) as previously described (Dinh et al., 2011). Nucleotide
sequencing of PeGFP, MmRFP, eGFP regions from viruses shown in
Table 1 as well the PCR ampliﬁed fragments spanning the entire
genome of VSV-PeGFP and VSV-PeGFPngR97S viruses isolated
from P0 of transfected culture supernatant was performed by
Euroﬁns MWG Operon (Huntsville, AL 35805). Primers used in
RT-PCR and sequencing are shown in Table 2.
Statistical analysis
Differences of viral titers in growth comparison and in competition assays were analyzed using the MIXED procedure (SAS
Inst. Inc., Cary, NC). Statistical model included Treatment as a
ﬁxed effect. All means are presented as least-squares means
(7SEM). A value of p o0.05 was considered to represent statistical signiﬁcance.
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